

Medical Policy Update

We develop and revise medical policies in response to changing medical technology. Benefit determinations are made based on the medical policy in effect at the time of the provision of services. Please review the following medical policies, all of which can be found on our Blue Advantage Resource Page at www.lablue.com/providers, click "Go to BA Resources" at the bottom of the screen, and then the "New/Revised Medicare Advantage Medical Policies" tab.

New Medical Policies

Effective May 1, 2025

Policy No.	Policy Name
043	Injectable Clostridial Collagenase for Fibroproliferative Disorders
088	valoctocogene roxaparvovec-rvox (Roctavian™)
091	Gene Therapy for Hemophilia B
092	emicizumab (Hemlibra®)
093	luspatercept-aamt (Reblozyl®)
094	betibeglogene autotemcel (Zynteglo®)

Effective June 1, 2025

095	bimatoprost Implant (Durysta™)
096	travoprost Implant (iDose TR®)
098	efgartigimod alfa (Vyvgart®), efgartigimod alfa and hyaluronidase human (Vyvgart® Hytrulo)
099	rozanolixizumab-noli (Rystiggo®)
100	imetelstat (Rytelo™)
101	denosumab (Prolia®)
102	romosozumab-aqqg (Evenity®)

Effective July 1, 2025

097	pasireotide Injection (Signifor LAR®)
103	Fecal microbiota, live-jslm (Rebyota™)
104	triamcinolone extended release intra-articular injection (Zilretta™)
105	spesolimab-sbzo (Spevigo®)
106	crovalimab-akkz (PiaSky®)
108	ravulizumab (Ultomiris™), eculizumab (Soliris®), biosimilars)
109	Prostatic Urethral Lift
110	Balloon Catheter use for Sinus Ostial Dilation and Septoplasty
111	Focal Treatments for Prostate Cancer

Revised Medical Policies

Effective June 1, 2025

015	Intra-Articular Hyaluronan Injections
030	Duplex Scanning